소아청소년 양극성장애 입원 환자의 약물 사용 특성 = 후향적 차트 분석 연구

다국어 초록 (Multilingual Abstract)

Objectives：This study was conducted in order to describe prescribing practices in treatment of pediatric bipolar disorder in a Korean inpatient sample.
Methods：We performed a retrospective chart review of 66 youths who had been hospitalized and diagnosed with bipolar disorder
according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria. Demographics, clinical characteristics, medications used, doses, and related adverse events were examined.
Results：Mood stabilizers and/or atypical antipsychotic medications were the primary treatment. Risperidone, valproate, and lithium were the most commonly used. Thirty seven patients (58.1%) were treated with combination therapy of an atypical antipsychotic and mood stabilizer for improvement of manic/mixed symptoms.
Conclusion：Combination pharmacotherapy was necessary for most patients in this admission sample group. Conduct of further studies will be needed for evaluation of treatment response according to the clinical characteristics, and the safety and efficacy of treatment for child and adolescent bipolar disorder.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• References

참고문헌 (Reference)

1 McClellan J, "Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder" 46 : 2007

2 Biederman J, "Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young" 10 : 185-192, 2000

3 Leverich GS, "The poor prognosis of childhood-onset bipolar disorder" 150 : 485-490, 2007

4 Barzman DH, "The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review" 14 : 593-600, 2004

5 Frazier JA, "Risperidone treatment for juvenile bipolar disorder: a retrospective chart review" 38 : 960-965, 1999

6 Conners CK, "Rating scales and checklists for child psychopharmacology" 21 : 809-843, 1985

7 Marchand WR, "Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review" 14 : 405-411, 2004

8 Goldstein TR, "Psychosocial functioning among bipolar youth" 114 : 174-183, 2009

9 Kowatch RA, "Pediatric bipolar disorder: emerging diagnostic and treatment approaches" 15 : 73-108, 2006

10 Stringaris A, "Pediatric bipolar disorder versus severe mood dysregulation:risk for manic episodes on follow-up" 49 : 397-405, 2010

11 Pavuluri MN, "Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania" 82 (82): S103-S111, 2004

12 Moreno C, "National trends in the outpatient diagnosis and treatment of bipolar disorder in youth" 64 : 1032-1039, 2007

13 Findling RL, "Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder" 46 : 1445-1453, 2007

14 Perlis RH, "Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEPBD)" 55 : 875-881, 2004

15 Kafantaris V, "Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study" 43 : 984-993, 2004

16 Pavuluri MN, "Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder" 16 : 336-350, 2006

17 Hunt J, "Irritability without elation in a large bipolar youth sample: frequency and clinical description" 48 : 730-739, 2009

18 Hunt JI, "Irritability and elation in a large bipolar youth sample: relative symptom severity and clinical outcomes over 4 years" 74 : e110-e117, 2013

19 Wozniak J, "How cardinal are cardinal symptoms in pediatric bipolar disorder? An examination of clinical correlates" 58 : 583-588, 2005

20 Findling RL, "Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder" 44 : 409-417, 2005

21 Geller B, "Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome" 65 : 1125-1133, 2008

22 Correll CU., "Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents" 69 (69): 26-36, 2008

23 Doey T., "Aripiprazole in pediatric psychosis and bipolar disorder:a clinical review" 138 (138): S15-S21, 2012

24 Biederman J, "An open-label trial of risperidone in children and adolescents with bipolar disorder" 15 : 311-317, 2005

25 Chang K, "An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression" 45 : 298-304, 2006

26 Wilens TE, "A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors" 13 : 143-152, 2003

27 Frazier JA, "A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder" 11 : 239-250, 2001

28 Pavuluri MN, "A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder" 43 : 859-867, 2004

29 Delbello MP, "A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania" 41 : 1216-1223, 2002

30 DelBello MP, "A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania" 45 : 305-313, 2006